Study finds that anti-ERBB2 inhibitors used in breast cancer treatment pose significant risks to pregnancy and fetal health, including higher likelihoods of congenital defects and intrauterine growth restriction. Researchers recommend careful monitoring and possibly discontinuing these drugs during pregnancy despite their effectiveness against cancer.
Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’
A Democratic congressman on Wednesday blasted a bipartisan set of proposals focused on addiction, arguing that current congressional efforts will barely scratch the surface of
July 19, 2023